Hyperleptinemia: implications on the inflammatory state and vascular protection in obese adolescents submitted to an interdisciplinary therapy.
The low-grade systemic inflammation seen in obesity may affect the actions of some adipose tissue-derived adipokines that are involved in the regulation of vascular function. We sought to verify whether hyperleptinemia may influence the inflammatory and atherogenic responses in obese adolescents undergoing interdisciplinary therapy. Thirty-four obese adolescents underwent interdisciplinary therapy for 1 year. Subjects were considered hyperleptinemic if they had baseline values of leptin above 20 ng/mL for boys and 24 ng/mL for girls. Both groups showed an improvement in body composition and a reduction in carotid intima-media thickness. However, only subjects in the non-hyperleptinemic group showed an increase in adiponectin concentration after therapy. Moreover, leptin concentration was positively correlated with adiponectin and inversely correlated with PAI-1 in this group. Hyperleptinemic state may impair the attenuation of inflammation in obese adolescents undergoing interdisciplinary therapy, particularly by impeding the increase in adiponectin concentration, which is directly involved in vascular protection.
Post-graduate Program of Nutrition, Universidade Federal de São Paulo, São Paulo, Brazil.
Priscila L
PL
Sanches
Marco T
MT
de Mello
Natália
N
Elias
Francisco A H
FA
Fonseca
Raquel M S
RM
Campos
June
J
Carnier
Aline
A
de Piano
Deborah C L
DC
Masquio
Patrícia L
PL
Silva
Lila M
LM
Oyama
Flavia C
FC
Corgosinho
Cláudia M O
CM
Nascimento
Lian
L
Tock
Carolina Ackel
CA
D'Elia
Sergio
S
Tufik
Ana R
AR
Dâmaso
D052242:Adiponectin / Q000097:blood*; D000273:Adipose Tissue / Q000473:pathology; D050154:Adiposity; D000293:Adolescent; D001786:Blood Glucose; D059168:Carotid Intima-Media Thickness; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000276:immunology; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood*; D008019:Life Style; D008297:Male; D009765:Obesity / Q000097:blood* / Q000276:immunology; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D061217:Weight Reduction Programs
D052242:Adiponectin; D001786:Blood Glucose; D020738:Leptin; D017395:Plasminogen Activator Inhibitor 1